GSK (GSK) Competitors

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Is GSK or AZN more profitable?

AstraZeneca has a net margin of 13.01% compared to GSK's net margin of 8.02%. GSK's return on equity of 18.08% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	8.02%	18.08%	9.56%
AstraZeneca	13.01%	17.76%	7.68%

Which has higher valuation and earnings, GSK or AZN?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£31.63B	2.05	£2.50B	£0.83	1,952.24
AstraZeneca	£56.50B	3.51	£8.71B	£5.31	2,406.78

Do institutionals & insiders hold more shares of GSK or AZN?

56.9% of GSK shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 0.2% of GSK shares are held by insiders. Comparatively, 0.1% of AstraZeneca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is GSK or AZN a better dividend stock?

GSK pays an annual dividend of GBX 0.62 per share and has a dividend yield of 0.0%. AstraZeneca pays an annual dividend of GBX 3.14 per share and has a dividend yield of 0.0%. GSK pays out 75.0% of its earnings in the form of a dividend. AstraZeneca pays out 59.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Do analysts recommend GSK or AZN?

GSK presently has a consensus price target of GBX 1,637.50, indicating a potential upside of 1.42%. AstraZeneca has a consensus price target of £134.25, indicating a potential upside of 5.05%. Given AstraZeneca's stronger consensus rating and higher possible upside, analysts plainly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
AstraZeneca	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media favor GSK or AZN?

In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 9 mentions for GSK and 8 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.58 beat GSK's score of 0.36 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AstraZeneca	2 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, GSK or AZN?

GSK has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Summary

AstraZeneca beats GSK on 12 of the 18 factors compared between the two stocks.